Novo Nordisk lifted by strong 1st-half sales and net profit

5 August 2021

Danish diabetes care giant Novo Nordisk’s (NOV: N) shares closed up nearly 5% at 611 Danish kroner yesterday, as it reported financials for the first half of 2021, showing that sales increased by 5% in kroner and by 12% at constant exchange ratels (CER) to 66.8 billion kroner $10.65 billion).

Sales in International Operations increased by 7% in kroner (13% at CER), and sales in North America Operations rose by 1% in kroner (11% at CER).

Net profit for the six months came in at 24.75 billion kroner, up 10%, while diluted earnings per share were 10.71 kroner, a rise of 12%. Novo Nordisk’s shares were up a further 3.8% to 634.40 kroner by late morning today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK